OncoMatch/Pancreatic Cancer (PDAC)/KRAS
Pancreatic Cancer (PDAC)KRAS Clinical Trials
KRAS mutations — predominantly G12D (~40%), G12V (~30%), and G12R (~15%) — are present in over 90% of pancreatic ductal adenocarcinomas and represent the most promising emerging target in PDAC. KRAS G12D inhibitors (MRTX1133 and others) and pan-KRAS inhibitors are in active early-phase trials with initial clinical signals. Trials also explore KRAS-targeted combination strategies including SHP2 inhibitors, MEK inhibitors, and immunotherapy.
Top recruiting KRAS Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count. See all 45 trials matched to your profile →
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Global Development, Inc.
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.